<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300803</url>
  </required_header>
  <id_info>
    <org_study_id>MOR208N001</org_study_id>
    <nct_id>NCT04300803</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL</brief_title>
  <official_title>An Expanded Access Protocol to Provide Intermediate Access to Tafasitamab (MOR208) for the Combination Treatment With Lenalidomide to Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinigen Healthcare Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MorphoSys AG</source>
  <brief_summary>
    <textblock>
      Expanded Access Program (EAP) to provide Tafasitamab (MOR208) to eligible patients with&#xD;
      relapsed or refractory Diffuse Large B Cell Lymphoma. Access to MorphoSys´ EAP can be&#xD;
      requested by contacting the respective CRO Clinigen (tafasitamab@clinigengroup.com).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is intended to provide access to patients with relapsed and/or refractory DLBCL&#xD;
      who had at least one prior anti-CD20 containing regimen. Patients with primary refractory&#xD;
      disease and double/triple hit status are also eligible. Patients considering this access&#xD;
      program should have no other therapeutic option, and are not eligible for other clinical&#xD;
      trials. The expanded access program (MOR208N001) is currently available in the United States&#xD;
      only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>DLBCL</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tafasitamab, 12 mg/kg. 4 week cycles: weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), loading dose Cycle 1, day 4. Cycle 4 onwards day 1, day 15 until disease progression</intervention_name>
    <description>Expanded Access Program, Non-Interventional Study</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria :&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Patient able to provide written informed consent&#xD;
&#xD;
          3. Histologically-confirmed diagnosis of DLBCL, including transformation from an earlier&#xD;
             diagnosis of indolent lymphoma.&#xD;
&#xD;
          4. Patients must have relapsed and/or refractory DLBCL, including primary refractory&#xD;
             disease and double/triple hit status, after at least 1 prior anti-CD20 containing&#xD;
             regimen.&#xD;
&#xD;
          5. Patients with a serious, life-threatening illness in which conventional therapies have&#xD;
             failed, are unsuitable and/or are unavailable and participation in ongoing relevant&#xD;
             clinical trials is not feasible.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have other histological type of lymphoma, e.g. indolent Non-Hodgkin&#xD;
             lymphoma (NHL), Primary mediastinal B-cell lymphoma (PMBL) or Burkitt Lymphoma&#xD;
&#xD;
          2. Patients who are not willing/able to take venous thromboembolic event prophylaxis&#xD;
             during the entire treatment period with lenalidomide&#xD;
&#xD;
          3. Patients with:&#xD;
&#xD;
               1. Known active bacterial and viral and fungal infections&#xD;
&#xD;
               2. Serology of chronic active viral Hepatitis B and/or C-Hepatitis&#xD;
&#xD;
               3. Known seropositivity for or history of active viral infection with human&#xD;
                  immunodeficiency virus (HIV)&#xD;
&#xD;
          4. Patients who are unable to participate in the lenalidomide REMS program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tafasitamab</keyword>
  <keyword>MOR00208</keyword>
  <keyword>MOR208</keyword>
  <keyword>monoclonal anti-CD19 antibody</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

